Moreover, although the study patients were different from those in the present study, Galloway et al.18 reported that, in their study using data from a large-scale patient registry, the risk of serious infections in patients with rheumatoid arthritis receiving anti-TNFα therapy is most commonly noted in the first 24 weeks of treatment. This evidence concerns the gene TNF and infection.